

## Dermatophytic Diseases: A Review of Tinea Pedis

Gyamfi Agyemang Julien<sup>1</sup>, Wezena Cletus Adiyaga<sup>3</sup>, Rahmat Alela-Emoma Saaka<sup>1</sup>, Samuel Sunwiale Sunyazi<sup>1</sup>, Abraham Titigah Batuiamu<sup>2</sup>, Daniel Abugri<sup>4</sup>, James Abugri\*<sup>1</sup>

### Affiliations

1. Department of Applied Chemistry and Biochemistry, C. K. Tedam University of Technology and Applied Sciences, Navrongo.
2. Tamale Teaching Hospital, Ministry of Health, Ghana
3. Department of Microbiology, School of Biosciences, University for Development Studies, Tamale.
4. Department of Biology, Alabama State University, USA

\*Corresponding Author

### Abstract

Studies in skin diseases, particularly *Tinea pedis* are very rare in Ghana leading to low investment in dermatological services in the country and the African continent. Globally, *Tinea pedis* affects about 15% of the world's population. Importantly, it is a major public health problem and socioeconomic issue. Currently, the most recommended treatment for *Tinea pedis* infection are polyenes, azoles, allylamines, and fluorocytosines. Although these drugs are effective, they do have adverse side effects and are limited in the clinical settings in developing countries especially Ghana.

**Method:** Research papers were collected from Pubmed, Google scholar, chemical abstracts, and journal websites, reporting both *in vitro* and *in vivo* information on *Tinea pedis*. General information on *Tinea pedis*, the methods of infection, transfer, treatment options, and resistance were obtained after screening the articles. Many agents are involved in cases of *Tinea pedis* but are predominantly caused by *Trichophyton rubrum* which feeds on the keratinous layer of the topmost skin of the foot causing skin discoloration, itching, and maceration. The disease is influenced by individual lifestyle, environmental conditions, and individual factors such as age, sex, and host immunity and is prevented by the maintenance of good personal hygiene.

*Tinea pedis* like other tinea infections are treated with both topical and systemic agents. The classes of medications used in the treatment of *Tinea pedis* are polyenes, azoles, allylamines, and fluorocytosines. *Tinea pedis* antifungal resistance development could be partly associated with incomplete medication and misuse of antifungal medications. Additionally, patients with serious underlying health conditions such as compromised immune systems like HIV/AIDS, diabetes, radiotherapy for cancer, and transplantation could complicate resistance.

**Conclusion:** Although, fungal diseases do not cause epidemics the increasing rate of fungal infections and therefore *Tinea pedis* has to be checked and prevented. High budgets are made in

the development of medications which mostly lose their effectiveness over time due to resistance development. Good personal hygiene is very effective but the available medications must be used appropriately for effective treatment and resistance avoidance. Infection prevention and control, tracking and data sharing, good and easily accessible antifungals, vaccines, and maintenance of personal and environmental hygiene are the topmost preventive measures against resistance development.

Keywords: Fungal infection; Ghana; Resistance, Anti-fungal, Drugs; Burden

## Introduction

Globally, it has been estimated that 15% of the world's human population are infected with fungal infections<sup>1,2</sup> with more than 70% having a high chance of getting infected by a fungal infection over their lifetime<sup>1</sup>. Fungal infections affect not only humans but also animals, plants, and cause havoc to the ecosystem<sup>3</sup>. Dermatophytes are a class of fungi that require keratin for growth and thus infect and colonize keratinous layers of the skin, nails, and hairs<sup>4,5,6</sup>. Tinea pedis or athlete's foot, a common type of dermatophytosis is associated with the skin between the toes but is capable of spreading to other parts of the foot; the sole, sides, and dorsum<sup>7</sup> and the body; groins, fingernails, and fingers. Tinea means fungal infection whereas pedis is a Latin word for infection of the foot<sup>7</sup>. Other forms of *Tinea* infections include tinea capitis which is an infection of the scalp<sup>8</sup> also called ringworm of the scalp, tinea corporis which is a contagious infection of the body, also called ringworm of the body<sup>9</sup>, tinea barbae which is an infection of the beard and mustache area<sup>10</sup>, tinea cruris or Jock itch which is an infection of moist and warm areas of the body including the groin and inner thighs<sup>11</sup> and tinea unguium also called onychomycosis, which is a dermatophyte infection of the toenails or fingernails<sup>12</sup>. Tinea pedis is very common among the homeless<sup>13</sup>. The disease co-morbid with other infections and thus often under-diagnosed. Due to its coexisting ability, the disease is found in some cases of onychomycosis, and tinea unguium serving as the reservoir of other dermatophytes<sup>14</sup>. When left untreated, the disease could lead to other conditions such as wounds, cellulitis, pain, and difficulty of ambulation<sup>15</sup>. Though the disease responds to inexpensive topical agents<sup>7</sup>, it develops a secondary bacterial infection due to the failure of patients to seek medical attention resulting from their uninformed knowledge of fungal infection<sup>15</sup>. Several drugs and creams are available for clearing *tinea* infections; nonetheless, good personal hygiene is one best way to prevent the disease. Mostly, topical agents are for the treatment of Tinea pedis but systemic agents can treat large area infections. Environmental considerations must be taken into account in selecting the right medication<sup>16</sup>, and for the avoidance of recurrence, treatment must continue for at least a week after the clinical clearing.

## Methodology

The work was done through a review of various publications obtained through online database search engines using PubMed, google scholars, mycology journals, infectious diseases websites, bibliography reviews, and newspaper publications. A total of 506 articles were obtained through the online database originating from several countries across the globe with the publication dates ranging from 1971 to 2020. Publications on dermatophytes were minimal in the first 10 years but

significantly increased in the last 10 years. Most of the retrieved papers were published starting from the year 2001 to 2020. Publications on dermatophytes were minimal in the first 10 years but significantly increased in the last 10 years. Most of the retrieved papers were published between the years 2001 and 2020. The search topics were Tinea pedis, antifungal susceptibility of Tinea pedis, dermatophytes, dermatophytes infections, and the prevalence of Tinea pedis in Ghana, Africa, and the world. The articles included works from other dermatophyte infections, bacterial, viral, and non-dermatophyte infections in addition to the research topic, Tinea pedis.




Figure 1: A PRISMA flow diagram of the screening procedure employed in identifying the various articles used in this review.




Figure 2: Publication types identified for the work




Figure 3: Grouped records of the years of publications of the publications used.

### Classification of causative agents

Dermatophytes are the main agents in Tinea pedis infection<sup>1,7</sup>. They cause skin and nail infection by infecting keratin of the top layer of the epidermis<sup>1</sup>. Fungi, the kingdom under which dermatophytes are classified, exist in the form of unicellular yeast and mold with highly branching structures called hyphae<sup>13</sup>. Dermatophytes are classified as antropophilic, which are those that cause infection only in humans and are transmitted from human to human, zoophilic, which includes those that infected animals but can cause inflammatory responses in humans who come in contact with infected animals, or geophilic, which are mainly found in the soil but occasionally cause infection in humans and animals<sup>17,18</sup>. They are grouped into three asexually reproducing forms; Epidermophyton, Microsporum and Trichophyton based on their primary location of interaction<sup>16,19</sup>. Among these genera, the Trichophyton contain the species that are most implicated in human dermatophytosis<sup>20</sup>. The main causative agent of interdigital Tinea pedis is the antropophilic species, Trichophyton rubrum<sup>17,18</sup> with other agents such as *T. mentagrophytes*<sup>21</sup>, *Epidermophyton floccosum*, and *T. tonsurans* which rarely occur in adult cases<sup>4</sup>. *T. rubrum* is found in some cases of onychomycosis<sup>22</sup>.

### ***Skin Microbiome Characterization***

Normal foot skin is colonized by harmless commensal microorganisms that include bacteria and fungi<sup>23</sup>. These microorganisms thrive very well in the distinct ecological niche of the foot that has a large number of sweat glands but lacks sebaceous glands that secrete antimicrobial fluids<sup>23</sup>. The warm and moist foot environment fostered by wearing closed shoes promotes the growth of fungi and gram-negative bacteria<sup>23</sup>. Xiaoping Liu and colleagues identified *Corynebacterium tuberculostearicum* and *Staphylococcus pettenkoferi*, *Pseudoclvibacter alba*, and *Brevibacterium paucivorans* as the prevalent bacteria species found on the feet of healthy individuals<sup>23</sup>. Comparatively, *Corynebacterium tuberculostearicum*, *Staphylococcus pettenkoferi*, *C. minutissimum*, and *P. sphaerophysae* were prevalent in patients with tinea pedis. *Cladosporium halotolerans*, *Phoma saxea*, *Aspergillus cibarius*, and *Rhodotorula mucilaginosa* are the most prevalent fungal species isolated from the feet of healthy individuals. In patients of tinea pedis, *Trichophyton rubrum*, *Cladosporium halotolerans*, *Candida parapsilosis*, and *Wallemia sebi* were the most abundant species isolated<sup>23</sup>. Tinea pedis presents a diverse community of microbes in different patients and different clinical presentations<sup>23</sup> as reported by Liu et. al<sup>24</sup>. The disease, as shown above, is associated with and complicated by the presence of other infecting organisms<sup>23</sup>. The diversity of bacteria and fungi species was shown to be higher in healthy controls than in tinea pedis patients, even though Staphylococcus and Trichophyton species were the most abundant bacteria and fungi species respectively<sup>23</sup>. The most prevalent strain of fungi in cases of tinea pedis is *Trichophyton rubrum* (~60% of cases)<sup>25</sup> followed by *T. mentagrophytes*<sup>26</sup> (~20-30%), *Epidermophyton floccosum* (~10%)<sup>1,6,16,27</sup> and *T. tonsurans* which rarely occurs in adult cases.

### **Clinical presentation**

There are three clinical forms of Tinea pedis; interdigital, hyperkeratotic, and vesticular, which are classified based on their pattern of skin manifestations<sup>2,13,16,28</sup>. Vikas and colleagues<sup>1</sup>,

however, classified tinea pedis into four clinical forms with the fourth class being ulcerative tinea pedis.

Interdigital Tinea pedis is the most common type of dermatophytes and occurs between the toes, mainly the fourth and fifth toes. It presents as macerated, dry or wet, scaly, and peeling of the interspaces of the toes and is classified as simplex if dry and asymptomatic, or complex if wet and symptomatic as a result of secondary bacterial infection.

Plantar (Hyperkeratotic) Tinea pedis affects the soles, heels, and sides of the foot with characteristic powdery scaling, redness of the soles, heels, and sides of the foot. The involvement of the plantar and lateral aspects of the foot with erythema and hyperkeratosis characterizes the moccasin foot.

Vesicobullous Tinea pedis occurs on the soles of the foot. It presents with an acute inflammatory reaction consisting of vesicles, pustules<sup>29</sup>, or blisters.

A patient may be asymptomatic or symptomatic by experiencing burning or itching. Infected toenails appear thickened, discolored, and dystrophic<sup>13</sup>.

Ulcerative tinea pedis is characterized by rapidly spreading ulcers, erosions, and lesions which typically occur in the web of the toes and occasionally affecting the soles of the foot. Large areas of the foot can be sloughed off. This type of tinea pedis is commonly followed by secondary bacterial infection and is mostly a disease of the immunocompromised and diabetic patients<sup>1</sup>. Symptoms such as malaise, pharyngitis, pyrexia, and cellulitis may accompany the infection.

### ***Modes of Transmission***

Fungi grow well in moist, dark, and warm environments. Poor hygiene, wearing dirty<sup>30</sup>, infected<sup>31</sup>, and occlusive footwear<sup>1,16,32</sup>, dirty socks, and wet feet provide the right conditions for infection and transmission of tinea pedis<sup>13,33</sup>. Tinea pedis is contagious and is transmitted through contact with fungal spores, arthroconidia from an infected person, surfaces, or objects<sup>1,13</sup>. Pets are a possible source of infection transmission.

### ***Infection and survival***

Infection is mounted through the interaction of the dermatophyte with the keratin of the top layer of the skin<sup>13,19</sup>. The arthroconidia of the dermatophyte invade the resistance mechanism (keratin layer, pH, and mucosal surfaces) of the host and penetrate its hyphae into the keratin layer of the skin. The fungi can adhere to the host due to the mannans in the glycoproteins of their cell wall. On infection, the dermatophytes use the carbons, nitrogen, and sulfur from keratin as energy sources thereby degrading the keratinous layer by the injection of permeases, enzymes of the cell wall, and hydrolytic enzymes. The tinea fungi do not penetrate the living tissues of the human host but colonize the horny keratinous layer<sup>2,19</sup>.

### ***Prevalence***

Fungal infections, in general, have been reported to be on a rapid rise recently even though these infections do not normally cause an outbreak<sup>19</sup>. Fungal diseases affect an estimated 15% of the population at any point in time with approximately 70% getting fungal infections over their lifetime<sup>34</sup>. Tinea pedis is found in almost all regions of the globe<sup>1,13</sup> and affects all classes of people<sup>2</sup> if appropriate personal hygiene instructions are not followed. The disease is influenced by individual lifestyle, environmental conditions, and individual factors such as age, sex, and host immunity<sup>14</sup>. An Individual's lifestyle, which does not obey hygienic procedures, can lead to infection while environmental and climatic conditions influence the condition due to its higher observation in areas with a humid climate, which tends to promote the growth of the pathogen<sup>1</sup> and lower in places where people do not usually wear shoes<sup>1</sup>. The prevalence of the disease varies with age with adults are being much more susceptible than children<sup>1,2,13,14,35</sup>. The area's most commonly affected are interdigital or pompholyx<sup>36</sup> areas of the foot. Also, males are more susceptible to the disease than females of the same or similar age<sup>2,16</sup>. Tinea pedis is also found to be prevalent among army personnel<sup>1</sup>, school children<sup>1,37,38,39,40,41,40,42</sup>, sailors, coal-miners, athletes, those attending public swimming baths<sup>1,37</sup>, or leisure centers<sup>37</sup>.

Dermatophyte infections are severe in people living with Acquired Immune Deficiency Syndrome (AIDS)<sup>1,13,19,37</sup>, diabetes mellitus patients (who have a 50% chance of infection)<sup>1,13,37,43,44</sup>, and those with a suppressed immune system due to medical procedures such as organ transplantation and chemotherapy<sup>1,13,19</sup>. Obesity also influences the severity of Tinea pedis<sup>1</sup> with non-completion of medication leading to disease recurrence and the development of resistance.

### ***Diagnosis***

Diagnosis of tinea pedis is based on clinical evaluation, laboratory evaluation, or fungal culture. The history of occurrence which would include the review of the patient for exposure to risk factors of the disease and clinical examination for the obvious appearance of the disease areas (symptoms) are important aspects of clinical diagnosis. In instances where appearance will not aid an obvious diagnosis which is common in cases of hyperkeratotic, ulcerative, or vesiculobullous tinea pedis, laboratory diagnosis using superficial skin scrapings<sup>13,14</sup> or nail clippings<sup>14</sup> from the infected areas is very helpful. A wet mount of the collected samples is made in potassium hydroxide and observed under the microscope<sup>13,16,45,46</sup>. KOH destroys skin cells leaving fungal cells for examination<sup>46</sup>. Fungal culture methods are the gold standard for the diagnosis of dermatophytosis and are used to confirm the condition due to the similarity of tinea pedis to other diseases<sup>16,47</sup> and the ineffectiveness of the KOH preparation for severe cases<sup>13</sup>. Severe cases present difficulties with the identification of the fungus in skin scrapings. Misdiagnoses may also occur because of a possible bacterial superinfection. Fungal culture takes one to two weeks for results to come in and is an expensive procedure. The methods are therefore only used when clinical and microscopy diagnosis techniques are inconclusive<sup>46</sup>.

### ***Complications***



Secondary cellulitis, erythema, lymphangitis, maceration, painful vesicles<sup>48</sup>, and fissures are complications that characterize the acute forms of tinea pedis while scaling, peeling, and toe maceration are associated with the chronic forms of the infection<sup>7</sup>. Complications associated with tinea pedis are more frequently associated with other conditions such as diabetes, chronic edema, suppressed immunity, hemiplegia, and paraplegia<sup>49</sup>.

### ***Prevention***

The best way of avoiding any dangers associated with foot ailments and other forms of infections is the maintenance of proper personal hygiene. Patients have to be educated on the importance of foot hygiene to prevent and minimize tinea pedis infections<sup>1</sup>. Effective personal hygiene keeping, dried feet, proper nail care, wearing of well-ventilated shoes with clean-dry socks<sup>1,13</sup>, and sanitizing footwears<sup>50</sup>. One way of ensuring dried shoes is by alternating shoes and socks frequently and using socks made of a material that draws moisture away from the feet. The usage of sandals and flip-flops is also very effective in preventing infection by allowing free movement of air around the feet. Foot powders are recommended for those working or living in areas the fungi have been identified<sup>13</sup>. The disease is prevalent in patients with compromised immunity<sup>51</sup> such as those infected with Human Immunodeficiency Virus (HIV), alcoholics, and those undergoing organ transplant. Such persons require proper diagnosis as a means of preventing severe tinea pedis. Effective implementation of the preventive measures listed above also helps eradicate infections through interpersonal contacts<sup>1</sup>.

### **Antifungal susceptibility testing (AFST)**

The ineffectiveness of a drug is a possible cause of resistance to antifungal agents. Two antifungal susceptibility-testing techniques based on broth microdilution methods<sup>52</sup> are used to determine the minimum inhibitory concentration (MIC) (MIC determination by reference techniques) of drugs used in treating tinea pedis and to detect drug-resistant strains development<sup>19</sup>. Strains with high MIC values are less likely to respond to antifungal agents<sup>52</sup>. AFST is determined by standardized procedures of Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference methods<sup>53,54</sup>. The Sensitive Yeast One and E-test methods are used for susceptibility testing.

### **Treatment options**

Antifungal agents used in the past to manage tinea pedis comprised of inorganic salts such as potassium permanganate and potassium iodide in ointments. Gentian violet, undecanoic, acetylsalicylic acids, and others followed these<sup>19</sup>. The disease, which is mostly on the top layer of the skin, is treated with topical agents and systemic agents when the area of infection is large with several failed attempts<sup>16</sup>, thus, systemic agents are more effective than topical agents<sup>55</sup>. A combination of topical and systemic medication can be more effective. People with underlying health conditions require oral or systemic therapy. The medications used in the treatment of the disease occurs in so many forms such as from creams to shampoo, lacquer, powders, ointments, sprays, and lotions<sup>16</sup>. Topical agents are effective for mild forms of Tinea pedis<sup>1</sup>. Cheaper over-



the-counter (OTC) agents work but have socioeconomic implications such as costly. For instance, terbinafine is more effective in the treatment of *T. pedis* but it is highly costly with one tablet causing about \$18.00 and the recommended doses is x times a day. Oral medication is effective for all types of *Tinea pedis*. There are four classes of systemic and topical antifungal medications used for treating fungal infections and therefore *Tinea pedis*<sup>56,57</sup>. These are; the polyenes antibiotics, the azole derivatives, the allylamines/thiocarbamates, and the fluoropyrimidines<sup>56,58</sup>. Topical antifungals require about two to four weeks while oral antifungals require about one to two weeks based on the medication chosen. Herbal medications have proved very effective in treating the disease condition<sup>59</sup>, Kakande and his colleagues carried out experimentation using *Tetradenia riparia*<sup>60</sup>.

### ***The polyenes***

These are produced by the *Streptomyces* species and have a broad-spectrum clinical antifungal effect. They work by inhibiting the biosynthesis of ergosterol which is an important component of the fungal plasma membrane by releasing oxidative agents. A typical example is amphotericin B, which may cause such as nephrotoxicity in patients<sup>56</sup>. These are normally given by injection into a vein (intravenous).

### ***Azoles***

They are broad-spectrum synthetic antifungals grouped as imidazole and triazoles based on the number of nitrogen groups. Like polyenes, azoles inhibit the biosynthesis of ergosterol but at the C-14 demethylation step. This inhibitory effect leads to the accumulation of intermediates that inhibits the function of ergosterol in the membrane. This exposes the membrane to damages and its transportability and proliferation are curtailed<sup>56</sup>. Examples of azoles are miconazole, ketoconazole, fluconazole, oxiconazole<sup>61</sup>, econazole, clotrimazole<sup>62</sup>, efinaconazole<sup>63,64</sup> and luliconazole<sup>65,66</sup>. Azoles are less toxic but some have major or minor side effects. Fluconazole has side effects that are damaging to health<sup>67</sup>. Reported side effects of ketoconazole include reduced production of testosterone and glucocorticoids. They also require about two to four weeks of treatment<sup>14</sup>.

### ***Clotrimazole***

This is an azole with enzyme inhibition property that kills and prevents reinfection of the tinea fungi. Some brands of clotrimazole are Lotrimin and Mycelex<sup>68</sup>. Clotrimazole is applied twice daily for four weeks for effective treatment.

### ***Miconazole, ketoconazole, fluconazole and oxiconazole, itraconazole***

These antifungals like clotrimazole are azoles with inhibitory effects<sup>69</sup> on growth enzymes, hence killing dermatophytes and prevents reinfection. The clinically used form of these is Micatin and is applied twice daily for two to four weeks<sup>68</sup>. These have however had the side effect of causing maceration in patients.

Other agents are imidazole, which is effective for interdigital Tinea pedis, and econazole which is effective for cutaneous tinea infections<sup>68</sup>.

### *Allylamines and thiocarbamates*

These are synthetic systemic antifungal agents. They inhibit ergosterol biosynthesis by preventing the cyclization of squalene to lanosterol<sup>56</sup> through squalene epoxidase inhibition<sup>37</sup>. This inhibition leads to a damaging effect on membrane synthesis. They are very effective in treating all forms of Tinea pedis<sup>68</sup>. They are therefore effective in treating dermatophytes<sup>37</sup>. Examples of allylamines are tolnaftate, ciclopirox, butenafine, naftifine, terbinafine with terbinafine the most used clinically.

### *Terbinafine*

This is an allylamine that kills fungi and prevents reinfection through growth enzyme inhibition. The common brand name is Lamisil, which exists in spray, and powder forms. It is very effective for treating tinea pedis<sup>37,70</sup> when applied once daily for a week. Common side effects associated with terbinafine are itching, rubor, and blistering. Fungal resistance to this antifungal is unfortunately established<sup>71</sup>.

### *Tolnaftate*

This is an allylamine that inhibits some growth enzymes and prevents infection and reinfection. Tinactin, Desenex spray, Absorbine, and Ting are some common brand names. The cream or gel is applied twice daily for two to six weeks. Some side effects associated with the use of tolnaftate are itching, redness, and peeling<sup>68</sup>.

### *Naftifine (naftin)*

They are a broad-spectrum synthetic derivative of allylamine that inhibits sterol biosynthesis for the formation of the fungal cell wall. The application of gel or cream twice daily for 4 weeks is effective for *T. rubrum* tinea pedis.

### *Butenafine (Mentax)*

This is a benzylamine that prevents fungal cell growth<sup>72</sup> by inhibiting sterol synthesis important for cell growth.

Benzyl amine, an allylamine derivative effective for refractory tinea pedis. Ciclopirox inhibits DNA, RNA, and protein synthesis<sup>68</sup>.

### *5-fluorocytosine (5-FC)*

5-FC limited spectrum of activity and is combined with amphotericin B for eliminating candidiasis. Nucleoside triphosphate from 5-FC conversion incorporated into the RNA sequence causes miscoding. It has been used to treat dermatophyte infections including Tinea pedis.

### *Combined steroid/antifungal agents*

Combination therapy is sometimes very effective for treating infections and for preventing the development of resistance. A combination of steroids with antifungal agents helps in the treatment of fungal infections. In conditions of no inflammation, the steroid is not needed, hence, monotherapy. A typical example of combination therapy is clotrimazole-betamethasone (Lotrisone)<sup>56</sup> and miconazole/urea<sup>73</sup> combinations.

Local ointments and soaps are effective for the treatment of the infection. Some of these ointments are 'Chocho' soap and cream, Joy ointment, Whitfield's ointment, and Castellani's paint. For effective treatment and avoidance resistance development, treatment must be continuous for at least a week after the clinical clearing of tinea pedis. Other drugs in various developmental stages are echinocandins, pneumocandins, and improved azoles that will target fungal protein and lipid biosynthesis<sup>56</sup>. Other agents used to supplement the antifungals are Aluminum acetate solution, Ammonium lactate lotion, and urea<sup>68</sup>.

### *Efficacy of the drugs*

The MIC is the mean inhibitory concentration, the mean concentration of the drug at which the organism's growth is inhibited by 50%. A high MIC value means low potency and vice versa. A comparison of the placebo effect to treatment has shown that treatment is more effective and some tinea pedis left untreated can become severe and lead to complications. Of the drugs used in treating Tinea pedis, terbinafine is the most effective followed by itraconazole though the difference not significant<sup>2</sup>. Fluconazole, griseofulvin, and ketoconazole are very close in potency and to itraconazole. All the drugs have reported side effects with the most common being diarrhea, nausea, headaches, rash, dermatitis, dizziness, and respiratory disorders.

### *How to use the medications*

To use the topical creams, gels, lacquers, or powders the area of infection and the surrounding parts are cleaned, dried and hands washed to avoid spreading to finger or other body parts<sup>4</sup>. The medicine is applied to the affected area and covered with loose gauze for the free circulation of air. Sandals or flip-flops must be worn after application or if possible patients should walk barefooted after medication. Failures of treatment should be reported to a medical practitioner or dermatologist six weeks after treatment.

### **Resistance**

Fungal resistance occurs when the fungus can survive in the presence of the drug made against it or appropriate therapy. It occurs as a result of the alteration of one or more genes making a previously susceptible population resistant<sup>58</sup>. Resistance commonly develops from incomplete medication regimens or the misuse of antifungal medications<sup>19,74</sup>. Treatment of patients with underlying health conditions such as AIDS and diabetes<sup>17</sup> and immunocompromised patients such as those undergoing cancer therapy and transplantation<sup>56</sup> is complicated and also leads to drug resistance. Besides, resistance may develop but remain undetected due to low routine

susceptibility testing hence complicating the situation. Even though fungal drug resistance is low compared to bacteria, the current rise in resistance poses a serious threat to humanity, animals, plants, and the ecosystem<sup>67</sup>. Margaret Hudson (2001) reported a yearly record of 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States. Resistance to allylamines<sup>37</sup> and azoles (*Candida albicans* to fluconazole) have been reported<sup>58</sup> and linked to the overuse of terbinafine. Some antifungals are more vulnerable to resistance than others. TruMDR1 and TruMDR2-ATP-binding genetic cassettes are linked to resistance development and pathogenic effects of dermatophytes<sup>37</sup>.

## **Mechanism of drug resistance**

Resistance mechanisms are the various defense strategies employed by microbes to overcome and survive<sup>19</sup> the host defenses, antibiotics, and other chemotherapies. The invading germ develops strategies such as alteration of surface lipids or proteins, use of different synthetic routes or synthesize compounds that counter the effect of the host's defense of antibiotics. Some mechanisms employed in resistance development include metabolic degradation of drugs, mutations, recombination, alteration of the drug target site, and target molecule overexpression<sup>37</sup>. Resistance development reduces the potency of drugs.

### *Polyenes*

Polyene resistance is from the alteration of membrane lipids and enhanced catalase activity, which helps reduce oxidative stress on the fungal cell. Amphotericin B has known secondary clinical resistance by some fungal strains (*Candida sp.*) even though intrinsic clinical resistance is not common. Polyenes are very toxic to the host<sup>75</sup>.

### *Azoles*

Resistance to azoles is very common, particularly in immunocompromised patients. Resistance develops from the alteration of membrane sterols leading to reduced membrane permeability. Mechanisms involved are stress adaptation, increased drug efflux, and overexpression of essential enzymes<sup>19</sup>. Resistance has been reported in *C. neoformans*<sup>56</sup> and clinical Trichophyton spp<sup>76</sup>.

### *Allylamines*

Resistance to allylamines develops through mutation of enzymes required in the action of antifungals, stress adaptation, increased drug efflux, and drug degradation<sup>19</sup>. Terbinafine resistance in *T. rubrum* was clinically confirmed by Colin et al. and Ditte et al. to be a result of amino acid substitution in squalene epoxidase<sup>77,78,79</sup>.

### *5-FC*

Occurs as a result of cytosine deaminase inhibition or mutations of enzymes required for 5-FC functioning<sup>56</sup>.

## **Methods of controlling resistance**

Infection prevention and control, tracking and data sharing, good and easily accessible antifungals, vaccines, and maintenance of personal and environmental hygiene<sup>67</sup> prevent resistance development. Also, resistance development can be controlled by delaying systemic azole therapy, effective dosing of medications, use of combination therapy with different actions, and use of systemic azoles with stimulators (e.g. cytokines) and efflux pump inhibitors<sup>58</sup>. Patient education to religiously follow prescribed treatment regimens also helps to control drug resistance.

### **New drug synthesis**

In new drug synthesis, of necessary consideration is the various mechanisms used in resistance development. Potent drugs should have no or less effect on the host. New drugs should be able to accumulate and persist at the site of application for a longer time<sup>19</sup>.

In conclusion, there is a need to using combination therapy as well as herbal treatment that has been shown to exert synergistic effectiveness.

### Reference

1. Kumar V, Tilak R, Prakash P, Nigam C, Gupta R. Tinea pedis: An Update. *Asian J Med Sci.* 2011;2(2):134-138. doi:10.3126/ajms.v2i2.4430
2. Bell-Syer SEM, Khan SM, Torgerson DJ. Oral treatments for fungal infections of the skin of the foot. *Sao Paulo Med J.* 2014;132(2):127. doi:10.1590/1516-3180.20141322T1
3. Fisher MC, Henk DA, Briggs CJ, et al. Emerging fungal threats to animal, plant and ecosystem health. *Nature.* 2012;484(7393):186-194. doi:10.1038/nature10947
4. Caravan NT, Elewski BE. Identifying Signs of Tinea Pedis: *J Drugs Dermatology.* 2015;14(10):42-47.
5. Hainer BL. Dermatophyte infections. *Am Fam Physician.* 2003;67(1):101-108. doi:10.1016/B978-008055232-3.60907-9
6. Carrillo-Muñoz AJ, Tur-Tur C, Cárdenes DC, Estivill D, Giusiano G. Sertaconazole nitrate shows fungicidal and fungistatic activities against *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Epidermophyton floccosum*, causative agents of tinea pedis. *Antimicrob Agents Chemother.* 2011;55(9):4420-4421. doi:10.1128/AAC.00219-11
7. Ely WJ, Rosenfeld S, Seabury MS. Diagnosis and management of tinea capitis. *Am Fam Physician.* 2014;90(10):702-711. doi:10.3928/0090-4481-19870101-08

8. Elewski B. Clinical diagnosis of common scalp disorders. *J Investig Dermatol Symp Proc.* 2005;10(3):190-193.
9. Panthagani A, Tidman M. Diagnosis directs treatment in fungal infections of the skin. *Practitioner.* 2015;259(1786):25-33.
10. Kuruvella T, Pandey S. Tinea Barbae. In: StatPearls. Treasure Island. *StatPearls Publ.* Published online 2020.
11. Pippin M, ML M. Tinea Cruris. In: StatPearls. Treasure Island (FL). *StatPearls Publ.* Published online 2020.
12. Harada T. Tinea unguium. *Med Mycol J.* 2011;52(2):77-95. doi:10.3314/jjmm.52.77
13. Carlo CJ, Bowe PM. Tinea pedis (athlete's foot). *Heal Care Homeless Pers.:*151-154.
14. Toukabri N, Dhieb C, El Euch D, Rouissi M, Mokni M, Sadfi-Zouaoui N. Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia. *Can J Infect Dis Med Microbiol.* 2017;2017. doi:10.1155/2017/6835725
15. Lipner SR, Sher RK. Management of Onychomycosis and Co-Existing Tinea Pedis Do Not Copy Penalties Apply. 2015;14(5):492-494.
16. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. *Am Fam Physician.* 2002;65(10):2095-2102.
17. Özcan D, Şekin D, Demirbilek M. In vitro antifungal susceptibility of dermatophyte strains causing tinea pedis and onychomycosis in patients with non-insulin-dependent diabetes mellitus: A case-control study. *J Eur Acad Dermatology Venereol.* 2010;24(12):1442-1446. doi:10.1111/j.1468-3083.2010.03666.x
18. Zheng H, Blechert O, Mei H, et al. Whole-genome resequencing of *Trichophyton rubrum* provides insights into population differentiation and drug resistance. *Mycopathologia.* 2020;185(1):103-112. doi:10.1007/s11046-019-00384-1
19. Martinez-Rossi NM, Peres NTA, Rossi A. Antifungal resistance mechanisms in dermatophytes. *Mycopathologia.* 2008;166(5-6):369-383. doi:10.1007/s11046-008-9110-7
20. Weitzman I, Summerbell RC. The dermatophytes. *Clin Microbiol Rev.* 1995;8(2):240-259. doi:10.1128/CMR.8.2.240
21. Oz Y, Qoraan I, Oz A, Balta I. Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey. *Int J Dermatol.* 2017;56(1):68-74. doi:10.1111/ijd.13402
22. Fabrizi V, Zacconi I, Principato M, et al. Toenail onychomycosis by *Trichophyton rubrum* and concurrent infestation with *Tyrophagus putrescentiae*. *Infez Med.* 2017;25(4):377-380.
23. Wang R, Song Y, Du M, et al. Skin microbiome changes in patients with interdigital tinea pedis. *Br J Dermatol.* 2018;179(4):965-968. doi:10.1111/bjd.16706
24. Liu X, Tan J, Yang H, et al. Characterization of Skin Microbiome in Tinea Pedis. *Indian J Microbiol.* 2019;59(4):422-427. doi:10.1007/s12088-019-00816-y



25. Ozkutuk A, Ergon C, Yulug N. Species distribution and antifungal susceptibilities of dermatophytes during a one year period at a university hospital in Turkey. *Mycoses*. 2007;50(2):125-129. doi:10.1111/j.1439-0507.2006.01333.x
26. Frías-De-león MG, Martínez-Herrera E, Atoche-Diéguez CE, et al. Molecular identification of isolates of the trichophyton mentagrophytes complex. *Int J Med Sci*. 2020;17(1):45-52. doi:10.7150/ijms.35173
27. Mohammadi R, Abastabar M, Mirhendi H, Badali H, Shadzi S. Use of Restriction Fragment Length Polymorphism to Rapidly Identify Dermatophyte Species Related to Dermatophytosis. 2015;8(6):4-9. doi:10.5812/jjm.8(6)2015.17296
28. Toukabri N, Corpogno S, Bougnoux ME, El Euch D, Sadfi-Zouaoui N, Simonetti G. In vitro biofilms and antifungal susceptibility of dermatophyte and non-dermatophyte moulds involved in foot mycosis. *Mycoses*. 2018;61(2):79-87. doi:10.1111/myc.12706
29. Hirschmann J V, Raugi GJ. Pustular tinea pedis. *J Am Acad Dermatol*. 2000;42(1):132-133. doi:10.1016/S0190-9622(00)90022-7
30. Sasagawa Y. Internal environment of footwear is a risk factor for tinea pedis. 2019;46:940-946. doi:10.1111/1346-8138.15060
31. Ishijima SA, Hiruma M, Sekimizu K, Abe S. Detection of Trichophyton spp . from footwear of patients with tinea pedis. 2019;13(4):207-211. doi:10.5582/ddt.2019.01060
32. Pichardo-Geisinger R, Mora CD, Newman J c, Arcury TA, Feldman SR, Quandt SR. Cormobidity of Tinea Pedis and Onychomycosis and Evaluation of Risk Factors in Latino Immigrant Poultry Processing and Other Manual Laborers. *South Med J*. 2014;107(6):374-379. doi:10.14423/01.SMJ.0000450705.67259.26
33. Ishijima SA, Hiruma M, Sekimizu K, Abe S. Detection of Trichophyton spp . from footwear of patients with tinea pedis. 2019;13(4):207-211. doi:10.5582/ddt.2019.01060
34. Ilkit M, Durdu M. Tinea pedis□: The etiology and global epidemiology of a common fungal infection. 2014;7828:1-15. doi:10.3109/1040841X.2013.856853
35. Perea S, Ramos MJ, Garau M, Gonzalez A, Noriega AR, Palacio ADEL. Prevalence and Risk Factors of Tinea Unguium and Tinea Pedis in the General Population in Spain. 2000;38(9):3226-3230.
36. Ishizaki S, Watanabe S, Sawada M, Ninomiya J, Otani T. A Case of Tinea Pedis in a Child Caused by Trichophyton interdigitale with Two Different Colony Phenotypes on Primary Culture. 2019;60(4):2-5.
37. Alipour M, Mozafari NA. Terbinafine susceptibility and genotypic heterogeneity in clinical isolates of Trichophyton mentagrophytes by random amplified polymorphic DNA (RAPD). *J Mycol Med*. 2015;25(1):e1-e9. doi:10.1016/j.mycmed.2014.09.001
38. Komba E V, Mgonda YM. The spectrum of dermatological disorders among primary school children in Dar es Salaam. *BMC Public Health*. 2010;10(1):765. doi:10.1186/1471-2458-10-765



39. Balci E, Gulgun M, Babacan O, et al. Prevalence and risk factors of tinea capitis and tinea pedis in school children in Turkey. 2014;64(5):2-5.
40. Andrews DM, Burns M. Common Tinea Infections in Children. *Am Fam Physician*. 2008;77(10):1415-1420. [www.aafp.org/afp](http://www.aafp.org/afp)
41. English MP, Gibson MD, Duncan EHL. STUDIES IN THE EPIDEMIOLOGY OF TINEA PEDIS. *Br Med J*. Published online 1960:573-576.
42. Adefemi SA, Odeigah LO, Alabi KM. Prevalence of dermatophytosis among primary school children in Oke-oyi community of Kwara state. 2011;14(1). doi:10.4103/1119-3077.79235
43. Chegour H, El Ansari N, El Mghari G, et al. Quels agents incriminés dans les mycoses du pied? Enquête auprès des diabétiques consultant au CHU Mohammed VI de Marrakech Hakima. *PanAfrican Med J*. 2014;17(228). doi:10.11604/pamj.2014.17.228.3131
44. Legge BS, Grady JF, Lacey AM. The incidence of tinea pedis in diabetic versus nondiabetic patients with interdigital macerations: a prospective study. *J Am Podiatr Med Assoc*. 2008;98(5):353-356. doi:10.7547/0980353
45. Karaman BF, Topal SG, Aksungur VL, Ünal I, I lkit M. Successive Potassium Hydroxide Testing for Improved Diagnosis of Tinea Pedis IS co py o co. *Cutis*. 2017;100(2):110-114.
46. Kelly BP. Superficial Fungal Infection. *Pediatr Rev*. 2012;33(4):22-37. doi:<https://doi.org/10.1542/pir.33-4-e22>
47. Hanna SA, Kirchhof GM. Mycosis fungoides mimicking tinea pedis. *CMAJ*. 2016;188:17-18. doi:10.1503/cmaj.160038/-/DC1
48. Kawai M, Suzuki T, Hiruma M, Ikeda S. A Retrospective Cohort Study of Tinea Pedis and Tinea Unguium in Inpatients in a Psychiatric Hospital. 2014;55(2):35-41.
49. Gül Ü, Çakmak SK, Özel S, Bingöl P, Kaya K. Skin disorders in patients with hemiplegia and paraplegia. *J Rehabil Med*. 2009;41(8):681-683. doi:10.2340/16501977-0394
50. Messina G, Burgassi S, Russo C, Ceriale E, Quercioli C, Meniconi C. Is it Possible to Sanitize Athletes' Shoes? *J Athl Train*. 2015;50(2):126-132. doi:10.4085/1062-6050-49.3.55
51. Crissey JT. Common dermatophyte infections. A simple diagnostic test and current management. *Postgrad Med*. 1998;103(2):191-192,197-200,205. doi:10.3810/pgm.1998.02.359
52. Cuenca-Estrella M. Antifungal drug resistance mechanisms in pathogenic fungi: From bench to bedside. *Clin Microbiol Infect*. 2014;20(6):54-59. doi:10.1111/1469-0691.12495
53. Sanguinetti M, Posteraro B. Susceptibility testing of fungi to antifungal drugs. *J Fungi*. 2018;4(3):1-16. doi:10.3390/jof4030110
54. Arsić-Arsenijević V, Branković M, Colović I, Dzamić A, Mitrović S, Ratkov E. [Antimycotics susceptibility testing of dermatophytes]. *Srp Arh Celok Lek*. 2010;138(7-8):518-525. doi:10.2298/sarh1008518a

55. Watanabe S. [Present state and future direction of topical antifungals]. *Nihon Ishinkin Gakkai Zasshi*. 1999;40(3):151-155. doi:10.3314/jjmm.40.151
56. Ghannoum MA, Rice LB. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. *Clin Microbiol Rev*. 1999;12(4):501-517. doi:10.1128/cmr.12.4.501
57. Carreira A, Ferreira JB, Pereira I, et al. Blad-containing oligomer: A novel fungicide used in crop protection as an alternative treatment for tinea pedis and tinea versicolor. *J Med Microbiol*. 2018;67(2):198-207. doi:10.1099/jmm.0.000675
58. Kanafani ZA, Perfect JR. Resistance to antifungal agents: Mechanisms and clinical impact. *Clin Infect Dis*. 2008;46(1):120-128. doi:10.1086/524071
59. Herrera-Arellano A, Martínez-Rivera M de los A, Hernández-Cruz M, et al. Mycological and electron microscopic study of *Solanum chrysotrichum* saponin SC-2 antifungal activity on *Candida* species of medical significance. *Planta Med*. 2007;73(15):1568-1573. doi:10.1055/s-2007-993744
60. Kakande T, Batunge Y, Eilu E, et al. Prevalence of Dermatophytosis and Antifungal Activity of Ethanolic Crude Leaf Extract of *Tetradenia riparia* against Dermatophytes Isolated from Patients Attending Kampala International University Teaching Hospital , Uganda. 2019;2019. doi:10.1155/2019/9328621
61. Mistik S, Ferahbas A, Koc AN, Ayangil D, Ozturk A. What defines the quality of patient care in tinea pedis? *J Eur Acad Dermatology Venereol*. 2006;20(2):158-165. doi:10.1111/j.1468-3083.2006.01396.x
62. Crowley PD, Gallagher HC. Clotrimazole as a pharmaceutical □: past , present and future . Published online 2014:611-617. doi:10.1111/jam.12554
63. Kawai M. Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis □: Efinaconazole 10 % Solution and Luliconazole. 2019;60(3):3-6.
64. Hur MS, Park M, Jung WH, Lee YW. Evaluation of drug susceptibility test for Efinaconazole compared with conventional antifungal agents. *Mycoses*. 2019;62(3):291-297. doi:10.1111/myc.12870
65. Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. *Br J Dermatol*. 2003;149(2):296-305. doi:10.1046/j.1365-2133.2003.05418.x
66. Salehi Z, Fatahi N, Taran M, et al. Comparison of in vitro antifungal activity of novel triazoles with available antifungal agents against dermatophyte species caused tinea pedis. *J Mycol Med*. 2020;30(2). doi:10.1016/j.mycmed.2020.100935
67. Hudson MMT. Antifungal resistance and over-the-counter availability in the UK: A current perspective. *J Antimicrob Chemother*. 2001;48(3):345-350. doi:10.1093/jac/48.3.345
68. Courtney MR. Tinea Pedis Medication. *Medscape*. Published online 2020:1-6.

69. Goh CL, Tay YK, Ali KB, Koh MT, Seow CS. In vitro evaluation of griseofulvin, ketoconazole, and itraconazole against various dermatophytes in Singapore. *Int J Dermatol*. 1994;33(10):733-737. doi:10.1111/j.1365-4362.1994.tb01523.x
70. Revankar SG, Nailor MD, Sobel JD. Use of terbinafine in rare and refractory mycoses. *Future Microbiol*. 2008;3(1):9-17. doi:10.2217/17460913.3.1.9
71. Hiruma J, Kitagawa H, Noguchi H, et al. Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. *J Dermatol*. 2019;46(4):351-353. doi:10.1111/1346-8138.14809
72. Gupta AK. Butenafine: an update of its use in superficial mycoses. *Skin Therapy Lett*. 2002;7(7):1-2,5. <http://www.ncbi.nlm.nih.gov/pubmed/12432425>
73. Mady OY, Al-madboly LA, Donia AA, Montes HM, Mady OY. Preparation , and Assessment of Antidermatophyte Activity of Miconazole – Urea Water-Soluble Film. 2020;11(April):1-16. doi:10.3389/fmicb.2020.00385
74. Al Balushi KA, Alzaabi MA, Alghafri F. Prescribing Pattern of Antifungal Medications at a Tertiary Care Hospital in Oman. *J Clin Diagn Res*. 2016;10(12):FC27-FC30. doi:10.7860/JCDR/2016/23591.9005
75. Georgopapadakou NH. Antifungals: Mechanism of action and resistance, established and novel drugs. *Curr Opin Microbiol*. 1998;1(5):547-557. doi:10.1016/S1369-5274(98)80087-8
76. Méndez-Tovar LJ, Manzano-Gayosso P, Velásquez-Hernández V, et al. [Resistance to azolic compounds in clinical Trichophyton spp. strains]. *Rev Iberoam Micol*. 2007;24(4):320-322. doi:10.1016/s1130-1406(07)70065-7
77. Osborne CS, Leitner I, Favre B, Ryder NS. Amino Acid Substitution in Trichophyton rubrum Squalene Epoxidase Associated with Resistance to Terbinafine. 2005;49(7):2840-2844. doi:10.1128/AAC.49.7.2840
78. Ditte MLS, Hare KR, Karin MJ, et al. crossm Emerging Terbinafine Resistance in Trichophyton□: Clinical Characteristics , Squalene Epoxidase Gene Mutations , and a. 2019;63(10):1-9.
79. Yamada T, Maeda M, Alshahni MM, et al. Terbinafine Resistance of Trichophyton Clinical Isolates Caused by Specific Point Mutations in the Squalene Epoxidase Gene. *Antimicrob Agents Chemother*. 2017;61(7). doi:10.1128/AAC.00115-17